Dr. Reddy’s Laboratories has secured permission from the Drug Controller General of India (DCGI) for importing the Sputnik V vaccine into India under emergency use authorization (EUA).

In February 2021, Dr. Reddy’s Laboratories commenced the process to seek the emergency use authorization for the Russian Covid-19 vaccine from the Indian drug regulator.

Last September 2020, Dr. Reddy’s Laboratories entered into a partnership with the Russian Direct Investment Fund (RDIF) for undertaking Sputnik V clinical trials and for distribution of the vaccine in India.

Apart from the clinical trials held in Russia by RDIF, phase 2/3 trials of the Covid-19 vaccine were taken up in India by Dr. Reddy’s Laboratories.

GV Prasad – Dr Reddy’s Laboratories Co-chairman and managing director said: “We are very pleased to obtain the emergency use authorsation for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute to our nation’s effort of vaccinating a signficant proportion of our population.”

Currently, the Sputnik V vaccine is approved for use in 60 countries. The Russian Covid-19 vaccine uses a couple of different vectors for the two shots in its vaccination course.

Sputnik V efficacy was established to be 91.6% as per a published article in the Lancet medical journal.

  Coronavirus, COVID-19, Dr. Reddy’s Laboratories, Drug Controller General of India, India, Russian Direct Investment Fund, Sputnik V vaccine, Wuhan Coronavirus